Lacosamide Ucb (Lacosamide)

Lacosamide works by enhancing the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and reduces hyper‑excitability. Additionally, it binds to CRMP‑2, a protein involved in neuronal development, further contributing to its anticonvulsant activity.

The appropriate dose of Lacosamide is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal function. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for Lacosamide during pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative treatments when appropriate. Breastfeeding mothers should discuss potential exposure with their doctor.

To order Lacosamide Ucb, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, Lacosamide offers a distinct mechanism by enhancing slow inactivation rather than fast inactivation. It is generally well tolerated and may be preferred when patients experience side effects from other agents, though individual response varies.

Lacosamide tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Lacosamide is administered orally as a tablet. Patients should swallow the tablet whole with water, preferably with or without food, as directed by their healthcare provider.

Serious risks include the emergence of suicidal thoughts or behavior, severe skin reactions such as Stevens‑Johnson syndrome, and cardiac arrhythmias. Patients should be monitored closely for mood changes, rash, or irregular heartbeats and seek immediate medical attention if these occur.

Lacosamide is contraindicated in individuals with known hypersensitivity to the drug or any of its components, and in patients with certain cardiac conduction disorders such as second‑ or third‑degree AV block without a pacemaker. Clinicians should evaluate each patient’s medical history before prescribing.